Antihypertensive medications and survival in patients with cancer: A population-based retrospective cohort study
Antihypertensive medications and survival in patients with cancer: A population-based retrospective cohort study
复制标题
DOI：
10.1016/j.canep.2013.09.001
复制
发表时间：
2013-12-01
影响因子：
2.6
通讯作者：
Minuk, Gerald Y.
中科院分区：
文献类型：
--
作者：
Holmes, Signy;Griffith, E. Jane;Minuk, Gerald Y.
背景：抗高血压药物与癌症患者生存之间的关系仍不清楚。目的：探讨抗高血压药物类别与癌症患者生存之间的关联。方法：将省级癌症登记数据与省级药物计划信息网络 (DPIN) 关联，纳入 2004 年至 2008 年期间患有肺癌 (n = 4241)、结直肠癌 (n = 3967)、乳腺癌 (n = 4019) 或前列腺癌 (n = 3355) 的患者。使用 Cox 回归分析来比较使用 β 受体阻滞剂 (BB)、血管紧张素转换酶的患者的生存情况抑制剂/受体阻滞剂 (ACEi/ARB)、钙通道阻滞剂 (CCB) 或噻嗪类利尿剂 (TD) 可以提高未使用任何这些抗高血压药物的患者的生存率。以 BB 作为参考类别，对仅使用一类抗高血压药物的患者的生存率进行比较。结果：与未使用抗高血压药物的人群相比，BB 对任何癌症的生存率均没有影响。 ACEi/ARB 的使用与乳腺癌（HR：1.22，95% CI：1.04-1.44）和肺癌（HR：1.11，95% CI：1.03-1.21）患者死亡率增加呈弱相关。乳腺癌患者使用 CCB（HR：1.22，95% CI：1.02-1.47）和肺癌患者使用 TD（HR：1.1，95% CI：1.01-1.19）死亡率也会增加。有强有力的证据（p 值
Background: The association between antihypertensive medications and survival in cancer patients remains unclear. Objectives: To explore the association between classes of antihypertensive drugs and survival in cancer patients. Methods: Provincial Cancer Registry data was linked with a Provincial Drug Program Information Network (DPIN) for patients with lung (n = 4241), colorectal (n = 3967), breast (n = 4019) or prostate (n = 3355) cancer between the years of 2004 and 2008. Cox regression analyses were used to compare survival of patients using beta blockers (BBs), angiotensin-converting enzyme inhibitors/receptor blockers (ACEi/ARB), calcium channel blockers (CCBs) or thiazide diuretics (TDs) to survival of patients who did not use any of these antihypertensive drugs. Survival of patients using only one class of antihypertensive drugs were compared to each other, with BBs as the reference class. Results: Compared to the antihypertensive drug non-user cohort, BBs had no effect on survival for any of the cancers. ACEi/ARBs use was weakly associated with increased deaths for breast cancer (HR: 1.22, 95% CI: 1.04-1.44) and lung cancer (HR: 1.11, 95% CI: 1.03-1.21) patients. Deaths were also increased with CCB use in patients with breast cancer (HR: 1.22, 95% CI: 1.02-1.47) and with TD use in lung cancer patients (HR: 1.1, 95% CI: 1.01-1.19). There was strong evidence (p-value